SNY vs. REGN
Compare and contrast key facts about Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: SNY or REGN.
Correlation
The correlation between SNY and REGN is 0.48, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
SNY vs. REGN - Performance Comparison
Loading data...
Key characteristics
SNY:
0.16
REGN:
-1.32
SNY:
0.44
REGN:
-1.91
SNY:
1.05
REGN:
0.76
SNY:
0.20
REGN:
-0.74
SNY:
0.45
REGN:
-1.29
SNY:
9.62%
REGN:
32.04%
SNY:
24.21%
REGN:
31.92%
SNY:
-46.65%
REGN:
-91.81%
SNY:
-13.51%
REGN:
-52.40%
Fundamentals
SNY:
$125.13B
REGN:
$61.99B
SNY:
$2.80
REGN:
$39.32
SNY:
17.84
REGN:
14.60
SNY:
0.82
REGN:
1.24
SNY:
2.77
REGN:
4.40
SNY:
1.47
REGN:
2.11
SNY:
$43.77B
REGN:
$14.09B
SNY:
$31.14B
REGN:
$11.96B
SNY:
$10.09B
REGN:
$4.98B
Returns By Period
In the year-to-date period, SNY achieves a 6.55% return, which is significantly higher than REGN's -19.69% return. Over the past 10 years, SNY has outperformed REGN with an annualized return of 3.81%, while REGN has yielded a comparatively lower 1.59% annualized return.
SNY
6.55%
-0.87%
3.80%
3.82%
4.92%
3.81%
REGN
-19.69%
0.05%
-28.87%
-41.90%
-0.16%
1.59%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
SNY vs. REGN — Risk-Adjusted Performance Rank
SNY
REGN
SNY vs. REGN - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
SNY vs. REGN - Dividend Comparison
SNY's dividend yield for the trailing twelve months is around 4.50%, more than REGN's 0.15% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
SNY Sanofi | 4.50% | 4.22% | 3.83% | 4.22% | 3.80% | 3.61% | 3.46% | 4.29% | 3.67% | 4.03% | 3.79% | 4.19% |
REGN Regeneron Pharmaceuticals, Inc. | 0.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
SNY vs. REGN - Drawdown Comparison
The maximum SNY drawdown since its inception was -46.65%, smaller than the maximum REGN drawdown of -91.81%. Use the drawdown chart below to compare losses from any high point for SNY and REGN. For additional features, visit the drawdowns tool.
Loading data...
Volatility
SNY vs. REGN - Volatility Comparison
The current volatility for Sanofi (SNY) is 8.13%, while Regeneron Pharmaceuticals, Inc. (REGN) has a volatility of 17.12%. This indicates that SNY experiences smaller price fluctuations and is considered to be less risky than REGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
SNY vs. REGN - Financials Comparison
This section allows you to compare key financial metrics between Sanofi and Regeneron Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SNY vs. REGN - Profitability Comparison
SNY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Sanofi reported a gross profit of 7.72B and revenue of 10.61B. Therefore, the gross margin over that period was 72.8%.
REGN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Regeneron Pharmaceuticals, Inc. reported a gross profit of 2.56B and revenue of 3.03B. Therefore, the gross margin over that period was 84.7%.
SNY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Sanofi reported an operating income of 2.29B and revenue of 10.61B, resulting in an operating margin of 21.5%.
REGN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Regeneron Pharmaceuticals, Inc. reported an operating income of 591.70M and revenue of 3.03B, resulting in an operating margin of 19.5%.
SNY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Sanofi reported a net income of 1.87B and revenue of 10.61B, resulting in a net margin of 17.7%.
REGN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Regeneron Pharmaceuticals, Inc. reported a net income of 808.70M and revenue of 3.03B, resulting in a net margin of 26.7%.